We then administered the preparations to the STAMTM mouse model [31] to test if the preparation could exacerbate NASH and liver fibrosis with a concomitant increase in CD163+ M2 macrophage and a decrease in IL−6. This evidence concerns the gene CD163 and metabolic dysfunction-associated steatohepatitis.